Yahoo Finance

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase ...

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize ...
The American Journal of Managed Care

Twice-Daily ESK-001 Treatment Shows Majority of Psoriasis Patients Achieve PASI 75

These 28-week data on twice-daily ESK-001 highlight the drug’s safety and efficacy among patients with psoriasis. ESK-001 is generally effective and well-tolerated among individuals with ...
Yahoo Finance

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

SOUTH SAN FRANCISCO, Calif., March 08, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize ...
Healio

‘Strong data’ support ESK-001’s potential as oral treatment for plaque psoriasis

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. ESK-001, a tyrosine kinase 2 inhibitor, may be a ...
Nasdaq

Alumis Inc. Completes Patient Enrollment for Phase 3 ONWARD Clinical Program Evaluating ESK-001 in Moderate-to-Severe Plaque Psoriasis

Alumis Inc. has announced the successful completion of patient enrollment in its pivotal Phase 3 ONWARD clinical program for ESK-001, a treatment for moderate-to-severe plaque psoriasis, involving ...
Business Wire

Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alumis Inc., a precision immunology company that is reimagining the discovery, development and treatment of autoimmune disorders, today announced that the ...
Nasdaq

Alumis Inc. Completes Patient Enrollment in LUMUS Phase 2b Trial of ESK-001 for Systemic Lupus Erythematosus, Topline Data Expected Q3 2026

Alumis Inc. has announced the completion of patient enrollment in its global LUMUS Phase 2b trial for ESK-001, a next-generation oral TYK2 inhibitor aimed at treating systemic lupus erythematosus (SLE ...